{"title":"STUDYING BRAIN BIOLOGY IN LIVING PEOPLE","authors":"Alexander Charney","doi":"10.1016/j.euroneuro.2025.08.517","DOIUrl":null,"url":null,"abstract":"<div><div>A goal of biomedical research is to advance knowledge of the molecular basis of human brain function. One way to achieve this goal is through studies of cells and molecules in samples of human brain tissue. As brain samples from living people (“LIV samples”) are largely unavailable for research, most such studies are conducted using brain samples from postmortem donors (“PM samples”). This practice, while necessary, is subject to four key limitations. First, the extent to which PM samples faithfully represent LIV samples at the molecular level has not been rigorously investigated. Second, in contrast to the living brain, the postmortem brain is by definition not capable of any meaningful function – therefore, the molecular basis of human brain functions like perception, mood, and memory cannot be fully established using PM samples. Third, the postmortem state is unsuitable for studying the molecular relationship between the brain and more readily accessible tissues - most importantly, the blood - and this hinders biomarker discovery. Fourth, valuable information about PM sample donors (e.g., neuroimaging data, deep clinical phenotyping information) is often not available to researchers, thus precluding comprehensive understanding of how functions emerge from the biological, electrophysiological, and anatomical features of the human brain.</div><div>The Living Brain Project (LBP) was designed to help address these limitations. The LBP is a translational research framework predicated upon the deep brain stimulation (DBS) procedure. From each LBP study participant the following is obtained: samples of the prefrontal cortex (PFC), peripheral blood samples obtained simultaneously with the PFC, intracranial electrical recordings, neuroimaging, and deep clinical phenotyping. To date, analyses of LBP data have identified (1) the safety of the PFC biopsy approach, (2) widespread biological differences between LIV samples and PM samples, (3) biological signatures of neurotransmission, (4) complex patterns of molecular communication between the brain and the blood, and (5) relationships between brain biology and structure. Overall, the LBP framework provides a blueprint for the safe, ethical, and scalable study of brain biology in living people and enables the investigation of fundamental questions about the brain that were previously unable to be studied.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"99 ","pages":"Page 30"},"PeriodicalIF":6.7000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Neuropsychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0924977X25006753","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
A goal of biomedical research is to advance knowledge of the molecular basis of human brain function. One way to achieve this goal is through studies of cells and molecules in samples of human brain tissue. As brain samples from living people (“LIV samples”) are largely unavailable for research, most such studies are conducted using brain samples from postmortem donors (“PM samples”). This practice, while necessary, is subject to four key limitations. First, the extent to which PM samples faithfully represent LIV samples at the molecular level has not been rigorously investigated. Second, in contrast to the living brain, the postmortem brain is by definition not capable of any meaningful function – therefore, the molecular basis of human brain functions like perception, mood, and memory cannot be fully established using PM samples. Third, the postmortem state is unsuitable for studying the molecular relationship between the brain and more readily accessible tissues - most importantly, the blood - and this hinders biomarker discovery. Fourth, valuable information about PM sample donors (e.g., neuroimaging data, deep clinical phenotyping information) is often not available to researchers, thus precluding comprehensive understanding of how functions emerge from the biological, electrophysiological, and anatomical features of the human brain.
The Living Brain Project (LBP) was designed to help address these limitations. The LBP is a translational research framework predicated upon the deep brain stimulation (DBS) procedure. From each LBP study participant the following is obtained: samples of the prefrontal cortex (PFC), peripheral blood samples obtained simultaneously with the PFC, intracranial electrical recordings, neuroimaging, and deep clinical phenotyping. To date, analyses of LBP data have identified (1) the safety of the PFC biopsy approach, (2) widespread biological differences between LIV samples and PM samples, (3) biological signatures of neurotransmission, (4) complex patterns of molecular communication between the brain and the blood, and (5) relationships between brain biology and structure. Overall, the LBP framework provides a blueprint for the safe, ethical, and scalable study of brain biology in living people and enables the investigation of fundamental questions about the brain that were previously unable to be studied.
期刊介绍:
European Neuropsychopharmacology is the official publication of the European College of Neuropsychopharmacology (ECNP). In accordance with the mission of the College, the journal focuses on clinical and basic science contributions that advance our understanding of brain function and human behaviour and enable translation into improved treatments and enhanced public health impact in psychiatry. Recent years have been characterized by exciting advances in basic knowledge and available experimental techniques in neuroscience and genomics. However, clinical translation of these findings has not been as rapid. The journal aims to narrow this gap by promoting findings that are expected to have a major impact on both our understanding of the biological bases of mental disorders and the development and improvement of treatments, ideally paving the way for prevention and recovery.